Exclusive Online Content
Absci First to Create & Validate De Novo Antibodies With Zero-Shot Generative AI
This breakthrough unlocks the potential to accelerate time to clinic by over 50% and increase probability of success in the clinic….
Celltrion & Rani Therapeutics Partner on Development of Oral Monoclonal Antibody Treatment
Rani Therapeutics Holdings, Inc. recently announced it has partnered with Celltrion for the development of RT-111, an orally administered ustekinumab biosimilar….
Transgene Receives Approval to Start a Phase 1 Trial of Novel IL-12-Armed Oncolytic Virus Given by Intravenous Administration
Transgene recently announced it has received clinical trial application (CTA) approval from the French National Agency for the Safety of Medicines and Health Products (ANSM) to proceed with a Phase 1 clinical trial of TG6050, a novel oncolytic….
SAB Biotherapeutics Novel DiversitAb Platform Proven to Develop Anti-Idiotype Antibodies to Help Treat Autoimmune Diseases
SAB Biotherapeutics recently announced results from a project in collaboration with global biotechnology leader CSL confirming that SAB’s DiversitAb platform can generate functional fully human anti-idiotype polyclonal….
IMUNON Enters Collaborative Research Agreement With The Wistar Institute’s Vaccine & Immunotherapy Center to Research IMUNON’s PLACCINE Vaccine Platform
IMUNON, Inc. and The Wistar Institute recently announced the signing of a first collaborative research agreement to research and develop new vaccine formulations utilizing IMUNON’s PLACCINE modality for the….
Purple Biotech & Mor Research Applications Announce Research Collaboration to Identify Promising Investigational Oncology Treatments
Purple Biotech Ltd. recently announced a research collaboration with Mor Research Applications that provides Purple Biotech first access to early stage oncology product candidates owned by….
Biognosys & Bruker Form Partnership for Advanced Proteomics CRO Services for Global Biopharma & Biomarker Customers
New strategic partnership aims to broaden access to Biognosys’ leading CRO services and Spectronaut® software tools for unbiased proteomics and epiproteomics….
Oncorus Announces Research Collaboration With Daewoong Pharmaceutical for the Development of Lipid Nanoparticle Formulations for mRNA Drug Candidates
Research collaboration leverages Oncorus’ proprietary ionizable amines, PEG lipids, LNP formulations, process development and manufacturing together with Daewoong’s mRNA expertise….
Gilead to Acquire All Remaining Rights to Potential First-In-Class Immunotherapy
Gilead Sciences, Inc. and Jounce Therapeutics, Inc. amended their existing license agreement for GS-1811 (formerly JTX-1811), enabling Gilead to buyout remaining contingent payments potentially due under….
Eyenovia Aims to Revolutionize Ophthalmology Devices With Microdose Array Print (MAP) Technology
While medical devices have seen incredible advancements over the last 100 years, ocular drug delivery systems have seen minimal progress; the standard eye dropper used today has gone largely unchanged….
Jazz Pharmaceuticals & Zymeworks Announce Jazz has Confirmed Opt-In & Advances Partnership
Jazz Pharmaceuticals plc and Zymeworks Inc. recently announced Jazz has exercised its option to continue with its exclusive development and commercialization rights to Zymeworks’ zanidatamab in key markets….
atai Life Sciences Initiates Phase 2b Proof-of-Concept Trial of RL-007 for Cognitive Impairment Associated With Schizophrenia
The Phase 2b proof-of-concept trial will evaluate the novel compound, RL-007, for pro-cognitive effects in patients with Cognitive Impairment Associated with Schizophrenia (CIAS)…..
Carrick Therapeutics & The Menarini Group Announce Clinical Trial Collaboration
Carrick Therapeutics and the Menarini Group recently announced a clinical trial collaboration and supply agreement that covers the execution of a Phase 2 clinical trial to evaluate the novel combination of….
Paratek Pharmaceuticals Announces Positive Top Line Data From Pilot Efficacy Study for the Treatment of Pulmonary Anthrax & Acceptance of the Second Procurement of NUZYRA Under BARDA Project BioShield
Paratek Pharmaceuticals, Inc. recently announced positive top line data from a pilot rabbit efficacy study evaluating NUZYRA’s effectiveness in the treatment of pulmonary anthrax. In the study, a 100% survival rate….
Adagene Announces Clinical Trial Collaboration to Evaluate Anti-CTLA-4 SAFEbody ADG126 in Combination With Roche’s Standard-of-Care for First-Line Advanced Liver Cancer
Adagene Inc. recently announced a clinical trial collaboration with Roche to evaluate the triple combination of Adagene’s ADG126 with Roche’s atezolizumab and bevacizumab in first-line treatment of….
Tarsus Announces Positive Topline Data from Phase 1b Callisto Trial & Initiates Phase 2a Carpo Human Tick Kill Trial Evaluating TP-05, a Novel, Oral Therapeutic for the Prevention of Lyme Disease
Tarsus Pharmaceuticals, Inc. recently announced positive topline results from the completed Phase 1b Callisto trial and the enrollment of the first subject in the Carpo Phase 2a trial…..
MoonLake Immunotherapeutics Screens First Patient in Phase 2 Study of the Nanobody Sonelokimab in Active Psoriatic Arthritis
MoonLake Immunotherapeutics AG recently announced the first subject has been screened in the US in a Phase 2 clinical study of the Nanobody sonelokimab in patients with….
Hovione & GEA announce a Strategic Collaboration to Advance Continuous Tableting
Hovione & GEA recently announced a strategic collaboration to advance Continuous Tableting. This partnership stemmed from a successful customer-supplier relationship spanning several years….
Syneos Health Extends Partnership With Medable; Continued Collaboration Will Accelerate Bringing Clinical Trials Closer to the Patient
Syneos Health recently announced it has extended its strategic partnership with Medable, the industry-leading technology platform for patient-centered clinical trials, as part of….
Sosei Heptares Receives $10-Million Milestone Payment in Discovery Collaboration With AbbVie Targeting Inflammatory Diseases
Sosei Group Corporation recently announced it has reached an important R&D milestone under its discovery collaboration with AbbVie, the global biopharmaceutical company, focused on inflammatory and autoimmune….
